Protocol Ledger

NCT04569747 · Phase II · ACTIVE NOT RECRUITING

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Interventional Phase II clinical trial protocol NCT04569747 sponsored by Dana-Farber Cancer Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-11 Enrollment: 393 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04569747
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)393 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04569747
Protocol FieldVerified Registry Value
NCT IdentifierNCT04569747
Consolidated Lead SponsorDana-Farber Cancer Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment393 participants (ACTUAL)
Registered Start Date2021-01-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI